Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anti-Infective Start-Ups See Opportunity In An Epidemiological Nightmare

This article was originally published in Start Up

Executive Summary

Infectious disease researchers have been warning for decades of the growing numbers of drug-resistant bacteria, and a certain subset of investors and companies sees this epidemiological nightmare as an alluring business opportunity. We profile three emerging anti-infective drug developers in this issue: Arsanis Biosciences, ContraFect, and Fedora Pharmaceuticals.

You may also be interested in...



Soon To Start Antibiotic Trial In China, MicuRx Gets $25M For U.S. Testing

Chinese-U.S. hybrid MicuRx, founded by Vicuron veterans, has strong preclinical and Phase I data for a novel antibiotic targeting Gram-positive infections. Its cross-border approach will soon support two mid-stage trials.

Soon To Start Antibiotic Trial In China, MicuRx Gets $25M For U.S. Testing

A six-year-old start-up founded by Vicuron veterans has strong preclinical and Phase I data for a novel antibiotic targeting Gram-positive infections. Its cross-border approach will soon support two mid-stage trials.

The Regulatory Pendulum Swings In Favor Of Antibiotics, But Will Investments Follow?

New incentives under the US government’s GAIN Act and FDA’s openness to faster development are helping put antibiotics back on investors’ radar screens, if not yet loosening their checkbooks.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

SC092250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel